Marshall Wace’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Marshall Wace’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-192,465	Closed	-$1.93M	–	2921
2023 Q4	$1.93M	Buy	192,465 +72,976	+61%	+$331K	﹤0.01%	1233
2023 Q3	$344K	Sell	119,489 -106,139	-47%	-$388K	﹤0.01%	1841
2023 Q2	$860K	Buy	+225,628	New	+$632K	﹤0.01%	1781
2022 Q2	–	Sell	-38,752	Closed	-$89K	–	3982
2022 Q1	$89K	Sell	38,752 -48,576	-56%	-$166K	﹤0.01%	3208
2021 Q4	$528K	Buy	87,328 +17,022	+24%	+$164K	﹤0.01%	2767
2021 Q3	$975K	Sell	70,306 -4,728	-6%	-$55.8K	﹤0.01%	2039
2021 Q2	$976K	Sell	75,034 -25,399	-25%	-$340K	﹤0.01%	1820
2021 Q1	$1.55M	Buy	+100,433	New	+$2.37M	0.01%	1450

Marshall Wace's GRCL Position: Q1 2024 in Review

Marshall Wace sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 192,465 shares — an estimated $1.93M sold.

Marshall Wace first reported a position in GRCL in Q1 2021 and held it in 8 quarters. The position peaked at $1.93M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Marshall Wace reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Marshall Wace sold 192,465 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $1.93M.
Marshall Wace first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 8 quarters.
Marshall Wace's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $1.93M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.